Diagnosing high-grade B-cell lymphoma Burkitt-like lymphoma, especially when it returns, requires careful examination and specialized testing to distinguish it from similar aggressive blood cancers and to guide treatment decisions in clinical trials.

Introduction: Who Should Undergo Diagnostics

If you experience symptoms that appear suddenly and worsen quickly, it’s important to seek medical attention without delay. High-grade B-cell lymphoma Burkitt-like lymphoma is an extremely fast-growing cancer, meaning that symptoms can emerge rapidly and progress within days or weeks. People who notice rapidly enlarging lumps, especially in the abdomen, neck, armpits, or groin, should contact their doctor promptly. Because this disease shares features with both Burkitt lymphoma (a rare, aggressive cancer of B-cells) and diffuse large B-cell lymphoma (another aggressive type), accurate diagnosis is essential to determine the right treatment approach.^[3]

Individuals who have been treated for Burkitt lymphoma or high-grade B-cell lymphoma and notice new symptoms should also undergo diagnostic testing to check whether the disease has returned. Recurrent lymphoma—when cancer comes back after treatment—needs immediate evaluation because it can be harder to treat than the original diagnosis. People with weakened immune systems, such as those living with HIV or who have received organ transplants, face higher risk for developing these lymphomas and should be especially alert to symptoms like unexplained fevers, rapid weight loss, persistent fatigue, or swelling in unusual places.^[1][3]

Because high-grade B-cell lymphoma Burkitt-like can affect many parts of the body—including the jaw, abdomen, kidneys, central nervous system, and other organs—symptoms vary depending on where the disease develops. Abdominal pain or swelling, nausea, vomiting, or changes in bowel habits may indicate that lymphoma is growing in the digestive system. If the disease spreads to the brain or spinal cord, symptoms might include headaches, confusion, vision changes, or weakness in parts of the body. Anyone experiencing these warning signs, particularly if they appear suddenly or worsen rapidly, should seek diagnostic testing right away.^[2][14]

Classic Diagnostic Methods

Diagnosing high-grade B-cell lymphoma Burkitt-like begins with a thorough physical examination. Your doctor will check for swollen lymph nodes in your neck, armpits, and groin, and will examine your abdomen for any masses or organ enlargement. A neurological exam, which tests how well your brain, spinal cord, and nerves are functioning, may also be performed, especially if there’s concern that the lymphoma has spread to the central nervous system. This exam looks for changes in coordination, sensation, reflexes, and mental function that could signal involvement of the brain or spinal cord.^[13]

Blood tests are an essential part of the diagnostic process. These tests can sometimes detect lymphoma cells circulating in the bloodstream, although not all cases will show this. Blood work also measures levels of lactate dehydrogenase (LDH), an enzyme that is often elevated in people with lymphoma. High LDH levels can indicate that cancer cells are growing rapidly and breaking down tissues. Additionally, blood tests check for infections that increase the risk of developing certain types of lymphoma, such as Epstein-Barr virus (EBV) or HIV. Understanding these risk factors helps doctors determine the subtype of lymphoma and plan appropriate treatment.^[13][1]

Imaging tests create detailed pictures of the inside of your body and help doctors see where lymphoma is located and how far it has spread. CT scans (computed tomography) and PET scans (positron emission tomography) are commonly used to examine the chest, abdomen, pelvis, and other areas where lymphoma may develop. If doctors suspect that the disease has reached the brain or spinal cord, they may order an MRI scan (magnetic resonance imaging), which provides detailed images of these structures. These imaging studies are crucial for staging the disease—determining how advanced it is—and for planning treatment.^[13]

The most definitive way to diagnose high-grade B-cell lymphoma Burkitt-like is through a lymph node biopsy. This procedure involves removing all or part of a swollen lymph node so that tissue can be examined under a microscope in a laboratory. The biopsy sample undergoes multiple tests, including histologic (microscopic tissue examination), immunohistochemistry (which identifies specific proteins on the surface of cells), and cytogenetic analysis (which looks for genetic changes in chromosomes). These tests help distinguish Burkitt-like lymphoma from other types of aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma or true Burkitt lymphoma.^[3][13]

A hallmark of Burkitt lymphoma is a translocation—a type of genetic rearrangement—involving the MYC gene. In high-grade B-cell lymphoma with features similar to Burkitt lymphoma, MYC translocation is often found along with rearrangements in other genes such as BCL2 or BCL6. These genetic findings are identified through molecular tests, which examine DNA and chromosomes under a microscope. Accurate identification of these gene rearrangements is critical because it affects treatment decisions. For instance, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (sometimes called “double-hit” or “triple-hit” lymphoma) is treated differently than standard diffuse large B-cell lymphoma.^[5][8]

Bone marrow aspiration and biopsy are procedures that collect samples from the bone marrow—the spongy tissue inside bones where blood cells are made. A needle is used to withdraw liquid marrow (aspiration) and a small piece of solid tissue (biopsy), usually from the hip bone. These samples are examined in a lab to determine whether lymphoma has spread to the bone marrow. Involvement of the bone marrow can affect prognosis and treatment planning.^[13]

In some cases, doctors perform a lumbar puncture, also known as a spinal tap, to check whether lymphoma has spread to the fluid surrounding the brain and spinal cord. This procedure involves inserting a thin needle between the bones of the lower back to collect a sample of cerebrospinal fluid. The fluid is then tested for cancer cells. Because Burkitt-like lymphoma has a high tendency to spread to the central nervous system, this test is often part of the initial evaluation or staging process.^[15]

Diagnostics for Clinical Trial Qualification

Clinical trials test new treatments or combinations of treatments to find better ways to manage high-grade B-cell lymphoma Burkitt-like, especially when the disease is recurrent or difficult to treat. Before enrolling in a clinical trial, patients must undergo specific diagnostic tests to confirm that they meet the study’s eligibility criteria. These tests ensure that the trial includes patients who are most likely to benefit from the experimental treatment being studied.^[11]

One of the most important requirements for clinical trial participation is confirmation of the lymphoma diagnosis through biopsy and molecular testing. Trials often require proof that the lymphoma has specific genetic features, such as MYC translocation or additional rearrangements in BCL2 or BCL6. This is because some trials are designed specifically for patients with these genetic profiles. Laboratory tests must show that the patient has high-grade B-cell lymphoma with Burkitt-like features rather than another type of lymphoma, as treatments can differ significantly between subtypes.^[5][8]

Staging is another critical component of clinical trial eligibility. Imaging tests such as CT scans and PET scans are used to determine the extent of disease in the body. Some trials accept only patients with advanced-stage disease (stage III or IV), while others may include patients with earlier stages. PET scans are particularly valuable because they can detect metabolically active cancer cells and help assess how well the disease is responding to treatment. Findings on a PET scan at the end of therapy are among the best predictors of treatment outcome.^[12]

Blood tests are routinely performed before clinical trial enrollment to evaluate overall health and organ function. These tests measure blood cell counts, liver enzymes, kidney function, and levels of substances like LDH and uric acid. Results from these tests help doctors determine whether a patient is healthy enough to tolerate the experimental treatment. For example, if kidney or liver function is impaired, certain chemotherapy drugs may not be safe to use.^[13]

For patients whose lymphoma has returned after previous treatment, additional biopsies may be required to confirm that the disease has recurred and to check whether the cancer cells have developed new genetic changes. Sometimes, lymphomas evolve over time and acquire additional mutations that make them resistant to treatment. Understanding these changes can help researchers design targeted therapies that address the specific biology of recurrent disease.^[9]

Bone marrow and cerebrospinal fluid testing may also be required for certain clinical trials, particularly those focusing on preventing or treating lymphoma in the central nervous system. Because Burkitt-like lymphoma frequently spreads to the brain and spinal cord, trials often include interventions aimed at reducing this risk. Baseline testing helps establish whether the disease has already reached these sites before treatment begins.^[15]